NCT06355583 - Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

February 1, 2026

Study Completion Date

May 1, 2027

Conditions

Acute Lymphoblastic LeukaemiaAcute Leukemia of Ambiguous LineageChronic Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic SyndromeAcute Myeloid Leukemia

Interventions

DRUG

EBX-102

EBX-102 is a white size 0 gastro-resistant hydroxypropyl methylcellulose (HPMC) capsule containing communities of dried, intestinal microorganisms extracted from rigorously screened pooled human stool samples obtained from volunteer accredited donors.

DRUG

Placebo

The capsules contain inactive ingredients microcrystalline cellulose and magnesium stearate.

Trial Locations (8)

B15 2WB

RECRUITING

University Hospitals Birmingham NHS Foundation Trust, Birmingham

LS9 7TF

NOT_YET_RECRUITING

Leeds Teaching Hospital NHS Trust, Leeds

NW1 2BU

RECRUITING

University College London Hospitals NHS Trust, London

SE5 9RS

RECRUITING

Kings College NHS Foundation Trust, London

W12 0NN

RECRUITING

Imperial College Healthcare NHS Trust, London

SW3 6JJ

RECRUITING

Royal Mardsen Hostpital, London

M13 9WL

NOT_YET_RECRUITING

Manchester University NHS Foundation Trust, Manchester

RECRUITING

Manchester University NHS Trust, Manchester

All Listed Sponsors

lead

Imperial College London

OTHER